Table 3.
The reported AEs of included studies
| System | Aripiprazole | Haloperidol | Tiapride | Risperidone |
|---|---|---|---|---|
| Neuromuscular system and mental symptom | Drowsiness:5.1 %(5/98)–58.1 %(18/31); | Drowsiness: 6.67 %(2/30)–82.4 %(14/17); | Dizziness: 3.1 %(3/97)–6.67 %(2/30); | Drowsiness:17.2 %(5/29); |
| Extrapyramidal symptoms: 6.45 %(2/33)–19.4 %(6/31); | Extrapyramidal symptoms: 40 %(12/30)–43.6 %(17/39); | Drowsiness: 3.23 %(1/31)–5.2 %(5/97); | Fatigue: 3.4 %(1/29); | |
| Headache: 2 %(2/98)–16.1 %(5/31); | Tremor: 19.4 %(6/31)–22.5 %(9/40); | Anxiety: 13.3 %(4/30); | Dizziness: 3.4 %(1/29); | |
| Akathisia:3.33 %(1/30)–6.3 %(2/32); | Headache: 58.8 %(10/17); | Sedation: 6.67 %(2/30); | Nausea: 3.4 %(1/29); | |
| Anxiety: 2 %(2/98)–6.45 %(2/31); Tremor: 3.23 %(1/31)–5 %(2/40); | Dizziness: 11.8 %(2/17); | Akathisia: 6.67 %(2/30); | ||
| Fatigue: 2 %(2/98)–9.7 %(3/31); | Emotional hypersensitivity: 11.8 %(2/17); | Fatigue: 3.1 %(3/97); | ||
| Dizziness: 2.44 %(1/41)–6.5 %(2/31); | Insomnia: 11.8 %(2/17); Irritability:11.8 %(2/17); Fatigue: 7.69 %(3/39); Nightmare: 5.9 %(1/17); | Headache: 2.1 %(2/97); | ||
| Insomnia: 1 %(1/98)–3.2 %(1/31); Sedation:12.5 %(4/32); | Insomnia : 2.1 %(2/97); | |||
| Slowness: 6.5 %(2/31); Tiredness: 4.88 %(2/41); | ||||
| Emotional hypersensitivity: 3.2 %(1/31); Irritability: 3.2 % (1/31); | ||||
| Nightmare: 3.2 %(1/31) | ||||
| Digestive system | Increased appetite: 3.2 %(1/31)–25.8 %(8/31); | Nausea/vomiting: 23.5 %(4/17); | Nausea: 3.1 %(3/97)–13.3 %(4/30); | Increased appetite: |
| Anorexia: 4.1 %(4/98)–15 %(6/40); Nausea: 2 %(2/98)–18.8 %(6/32); | Nausea: 16.1 %(5/31); | Anorexia: 3.23 %(1/31)–4.1 %(4/97); | 27.6 %(8/29); | |
| Nausea/vomiting:1 %(1/98)–29 %(9/31); | Gastrointestinal disturbances: 11.8 %(2/17); | Nausea/vomiting: 2.1 %(2/97); | Abdominal pain: 6.9 %(2/29); | |
| Decreased Appetite: 12.9 %(4/31); Abdominal pain 9.7 %(3/31); | Anorexia: 7.5 %(3/40)–11.8 %(2/17); | |||
| Gastrointestinal disturbances: 6.5 %(2/31); Dyspepsia: 3.1 %(1/32); | Constipation: 6.45 %(2/31); | |||
| Abnormal liver function: 1 %(1/98); | Increased appetite: 5.9 %(1/17) | |||
| Ocular region | Blurred vision: 3.2 %(1/31)–9.7 % (3/31) | - | - | Blurred vision: 10.3 %(3/29); |
| Endocrine system | Weight gain: 1 %(1/98); Polydipsia: 3.2 %(1/31) | - | - | - |
| Urinary system | Nocturia: 3.2 %(1/31) | Nocturia: 5.9 %(1/17); | Nocturia: 1 %(1/97)–3.23 %(1/31); | Diurnal Urinary incontinency: 13.8 %(4/29); |
| Cardiovascular system | Elecrocardiogram QT prolonged: 6.3 %(2/32); | Electrocardiographic abnormality: 6.45 %(2/31)–10 %(4/40); | - | - |
| Electrocardiographic abnormality: 2.5 %(1/40)–6.45 %(2/31); | Chest discomfort: 11.8 %(2/17) | |||
| Chest discomfort: 3.2 % (1/31) | ||||
| Respiratory system | Nasopharyngitis: 12.5 %(4/32); | - | - | - |
| Upper respiratory tract infection: 3.1 %(1/32); | ||||
| Skin | Itches: 3.2 %(1/31); | - | - | Itches: 10.3 %(3/29); |
| Others | Dry mouth: 6.5 %(2/31)–6.67 %(2/30); | Dry mouth: 5 %(2/40)–19.4 %(6/31); | Dry mouth: 10 %(3/30); | - |
| Tiredness: 15.4 %(6/39); Joint pain: 11.8 %(2/17); | ||||
| Febrile sense: 5.9 %(1/17); | ||||
| School refusal: 5.9 %(1/17); |